Macquarie Group Ltd. decreased its stake in Haemonetics Corp. (NYSE:HAE) by 15.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 607,172 shares of the company’s stock after selling 112,689 shares during the period. Macquarie Group Ltd. owned 1.18% of Haemonetics Corp. worth $17,602,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in HAE. Hermes Investment Management Ltd. boosted its stake in Haemonetics Corp. by 21.5% in the second quarter. Hermes Investment Management Ltd. now owns 626,624 shares of the company’s stock valued at $18,166,000 after buying an additional 111,029 shares in the last quarter. California Public Employees Retirement System boosted its stake in Haemonetics Corp. by 4.3% in the second quarter. California Public Employees Retirement System now owns 102,700 shares of the company’s stock valued at $2,977,000 after buying an additional 4,200 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Haemonetics Corp. by 8.3% in the second quarter. Ameriprise Financial Inc. now owns 316,311 shares of the company’s stock valued at $9,173,000 after buying an additional 24,245 shares in the last quarter. Mason Street Advisors LLC acquired a new stake in Haemonetics Corp. during the second quarter valued at about $289,000. Finally, Barclays PLC boosted its stake in Haemonetics Corp. by 482.8% in the first quarter. Barclays PLC now owns 40,697 shares of the company’s stock valued at $1,384,000 after buying an additional 33,714 shares in the last quarter. Hedge funds and other institutional investors own 98.96% of the company’s stock.

Institutional Ownership by Quarter for Haemonetics Corp. (NYSE:HAE)

Shares of Haemonetics Corp. (NYSE:HAE) traded up 1.09% during trading on Friday, hitting $39.89. The stock had a trading volume of 90,491 shares. Haemonetics Corp. has a 52-week low of $25.98 and a 52-week high of $39.94. The firm’s 50-day moving average is $36.16 and its 200 day moving average is $33.30. The firm’s market cap is $2.06 billion.

Haemonetics Corp. (NYSE:HAE) last released its quarterly earnings results on Monday, November 7th. The company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.11. The company earned $220.30 million during the quarter, compared to analysts’ expectations of $210.72 million. Haemonetics Corp. had a positive return on equity of 10.99% and a negative net margin of 6.48%. Haemonetics Corp.’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.44 EPS. On average, analysts expect that Haemonetics Corp. will post $1.50 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Haemonetics Corp. (HAE) Shares Sold by Macquarie Group Ltd.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/27/haemonetics-corp-hae-shares-sold-by-macquarie-group-ltd.html.

Several equities analysts have weighed in on HAE shares. Off Wall Street started coverage on Haemonetics Corp. in a report on Friday, October 14th. They set a “sell” rating and a $24.00 price target for the company. CJS Securities cut Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 price target for the company. in a report on Tuesday, September 20th. Sidoti cut Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a report on Monday, August 15th. Benchmark Co. raised their price target on Haemonetics Corp. from $32.00 to $34.00 and gave the company a “hold” rating in a report on Monday, November 7th. Finally, Jefferies Group raised their price target on Haemonetics Corp. from $32.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $34.57.

Haemonetics Corp. Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Stock Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related stocks with our FREE daily email newsletter.